BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.57.

Several equities analysts have recently issued reports on the stock. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target on the stock. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $11.00 target price (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock traded up $0.04 on Friday, hitting $7.74. The company had a trading volume of 2,747,564 shares, compared to its average volume of 2,755,519. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $9.50. The company has a market cap of $1.62 billion, a PE ratio of -12.69 and a beta of 1.85. The business has a 50-day simple moving average of $8.14 and a 200-day simple moving average of $7.85.

Remove Ads

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Counterweight Ventures LLC grew its stake in BioCryst Pharmaceuticals by 591.7% in the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock valued at $710,000 after purchasing an additional 79,884 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of BioCryst Pharmaceuticals by 40.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after buying an additional 86,571 shares in the last quarter. Principal Financial Group Inc. increased its holdings in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after buying an additional 375,890 shares during the last quarter. Fisher Asset Management LLC raised its position in BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in BioCryst Pharmaceuticals by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company's stock valued at $14,349,000 after acquiring an additional 102,860 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.